Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34+ -Selected to CD3/CD19-Depleted Grafts in a Retrospective Multicenter Study

Frontiers in Immunology
E Salzmann-ManriqueUlrike Koehl

Abstract

Rapid immune reconstitution (IR) following stem cell transplantation (SCT) is essential for a favorable outcome. The optimization of graft composition should not only enable a sufficient IR but also improve graft vs. leukemia/tumor effects, overcome infectious complications and, finally, improve patient survival. Especially in haploidentical SCT, the optimization of graft composition is controversial. Therefore, we analyzed the influence of graft manipulation on IR in 40 patients with acute leukemia in remission. We examined the cell recovery post haploidentical SCT in patients receiving a CD34+-selected or CD3/CD19-depleted graft, considering the applied conditioning regimen. We used joint model analysis for overall survival (OS) and analyzed the dynamics of age-adjusted leukocytes; lymphocytes; monocytes; CD3+, CD3+CD4+, and CD3+CD8+ T cells; natural killer (NK) cells; and B cells over the course of time after SCT. Lymphocytes, NK cells, and B cells expanded more rapidly after SCT with CD34+-selected grafts (P = 0.036, P = 0.002, and P < 0.001, respectively). Contrarily, CD3+CD4+ helper T cells recovered delayer in the CD34 selected group (P = 0.026). Furthermore, reduced intensity conditioning facilitated faster immune recov...Continue Reading

References

Jan 1, 1990·Journal of Clinical Laboratory Analysis·D WienerD T Rowlands
Mar 1, 1997·The Journal of Pediatrics·W M Comans-BitterJ J van Dongen
Dec 12, 2001·Blood Reviews·F AversaM F Martelli
Jan 9, 2003·The Journal of Laboratory and Clinical Medicine·Steven M DevineJohn F DiPersio
Aug 23, 2003·Biostatistics·R HendersonA Dobson
Nov 12, 2003·The Journal of Allergy and Clinical Immunology·William T ShearerUNKNOWN Pediatric AIDS Clinical Trials Group
Jun 9, 2004·Blood Reviews·Thomas KlingebielDietrich Niethammer
Aug 7, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Matthias EyrichPaul G Schlegel
Nov 6, 2004·Blood Cells, Molecules & Diseases·Peter LangDietrich Niethammer
Nov 3, 2005·Leukemia & Lymphoma·Axel SchulenburgGerda Leitner
Jul 19, 2006·British Journal of Haematology·David I MarksJacqueline M Cornish
Dec 14, 2006·Transplantation·Martin S Zand
Jul 24, 2008·Bone Marrow Transplantation·L M BallUNKNOWN EBMT Paediatric Working Party
Nov 26, 2008·Bone Marrow Transplantation·P Lang, R Handgretinger
Mar 14, 2009·Lancet·James L M FerraraErnst Holler
Jul 10, 2009·Clinical Immunology : the Official Journal of the Clinical Immunology Society·R van GentK Tesselaar
Jun 2, 2010·Haematologica·Jacopo Peccatori, Fabio Ciceri
Aug 6, 2011·Scandinavian Journal of Immunology·E J H SchatorjéE de Vries
Mar 17, 2012·Scandinavian Journal of Immunology·E J H SchatorjéE de Vries

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Software Mentioned

R
JM package
BIAS

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.